

# Admedus Ltd

19:13 18 Feb 2019

## Admedus receives first data from animal study on heart valve device

Admedus Ltd (ASX:AHZ) has received interim data from the animal study of its single-piece 3D aortic valve, which involved five sheep being implanted and monitored for five months.

Data collected from the first four sheep suggests that the device can be implanted safely and has the potential to deliver meaningful clinical benefits.

Following the positive findings in this feasibility study, Admedus now confirms it could initiate a first-in-human clinical trial earlier than expected.

The study has demonstrated that these stentless valves can be implanted with reasonable ease, without any major adverse event.

**READ:** Admedus secures \$8.6 million as Sio Partners becomes substantial holder

Admedus chief medical officer Dr Kiran Bhirangi said: "The purpose of this feasibility study is to assess whether there is merit to progress to a larger animal study, and human clinical trials - and the results we have so far strongly support this.

"The findings are very encouraging for several reasons. The sheep model is well accepted and a good predictor of the effectiveness of the technology."

Proven resistance to calcification

Admedus CEO Wayne Paterson said: "Calcification is a major issue for surgeons and patients today when treating valvular disease.

"Our ADAPT® tissue is the only product of its kind that has data demonstrating ten years without calcification or degradation. Combining this unique benefit with the first and only single piece 3D valve could be a major disruption in the treatment strategies for patients in the future.

Potential market leader in US\$12 billion market

"ADAPT® TAVR would be a breakthrough for patients needing valve replacement.

"The TAVR market is expected to be \$US12 billion by 2025. If the earlier results translate to true clinical superiority, ADAPT® TAVR could be well placed to be the market leader.

Preliminary data but well-studied

"It's important to acknowledge the preliminary nature of this data. However, the

**Price:** 0.11

**Market Cap:** \$64.99 m

### 1 Year Share Price Graph



January 2019 October 2019 January 2020

### Share Information

**Code:** AHZ

**Listing:** ASX

**52 week High Low**  
0.13 0.029

**Sector:** Pharma & Biotech

**Website:** www.admedus.com

### Company Synopsis:

Admedus Ltd (ASX:AHZ) is a diversified healthcare company. &nbsp;.

action@proactiveinvestors.com

combination of a novel single-piece 3D aortic valve and the ADAPT® technology which has been studied for ten years and is already used in over 16,000 patients is showing demonstrable clinical benefits."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).